| Identification | Back Directory | [Name]
LUF6096 | [CAS]
1116652-18-6 | [Synonyms]
LUF6096
N-[2-(3,4-dichloroanilino)quinolin-4-yl]cyclohexanecarboxamide | [Molecular Formula]
C22H21Cl2N3O | [MDL Number]
MFCD18251557 | [MOL File]
1116652-18-6.mol | [Molecular Weight]
414.33 |
| Chemical Properties | Back Directory | [Melting point ]
226-227 °C(Solv: ethyl acetate (141-78-6)) | [Boiling point ]
612.0±55.0 °C(Predicted) | [density ]
1.370±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 20 mg/mL (48.27 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [pka]
12.59±0.20(Predicted) | [color ]
White to pink |
| Hazard Information | Back Directory | [Uses]
LUF6096, a potent allosteric enhancer of the adenosine A3 receptor, is able to allosterically enhance agonist binding. LUF6096 shows low orthosteric affinity for any of the adenosine receptors. LUF6096 shows protective effects in myocardial ischemia/reperfusion injury[1][2]. | [in vivo]
LUF6096 (twice i.v. bolus for 0.5 mg/kg or single i.v. bolus for 1 mg/kg) protects against myocardial ischemia/reperfusion injury in dogs[1]. | Animal Model: | Adult mongrel dogs (15-25 kg) were subjected left anterior descending (LAD) coronary artery occlusion and reperfusion[1] | | Dosage: | Twice i.v. bolus for 0.5 mg/kg or single i.v. bolus for 1 mg/kg | | Administration: | I.v. bolus | | Result: | Produced a marked reduction in infarct size (～50% reduction) compared with vehicle-treated dogs. |
| [References]
[1] Heitman LH, et, al. A series of 2,4-disubstituted quinolines as a new class of allosteric enhancers of the adenosine A3 receptor. J Med Chem. 2009 Feb 26;52(4):926-31. DOI:10.1021/jm8014052
[2] Du L, et, al. Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A? adenosine receptor. J Pharmacol Exp Ther. 2012 Jan;340(1):210-7. DOI:10.1124/jpet.111.187559 |
|
|